Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction

Future HIV Therapy

Volumn 2, Issue 3, 2008, Pages 271-280

  Rumbaugh, Jeffrey A ^a   Steiner, Joseph ^a   Sacktor, Ned ^a   Nath, Avindra ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Excitotoxicity; Gp 120; HAART; HIV demenia; MMP; Nitrosative stress; Oxidative stress; Tat

Indexed keywords

ANTIOXIDANT; ANTIRETROVIRUS AGENT; CEP 1347; CYCLIN DEPENDENT KINASE INHIBITOR; DULOXETINE; ERYTHROPOIETIN; FLAVOPIRIDOL; GLUTAMATE RECEPTOR ANTAGONIST; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INTEGRASE INHIBITOR; LEXIPAFANT; LITHIUM; MATRIX METALLOPROTEINASE INHIBITOR; MEMANTINE; METHADONE; MINOCYCLINE; N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; NEUROPROTECTIVE AGENT; NIMODIPINE; OLOMOUCINE; PENTOXIFYLLINE; PEPTIDE T; PLACEBO; PROTEIN KINASE C INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSCOVITINE; SELEGILINE; UNINDEXED DRUG; VALPROIC ACID;

ANTIINFLAMMATORY ACTIVITY; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PSYCHOMOTOR DISORDER; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS VIRULENCE;

EID: 52349117808     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.3.271     Document Type: Review

References (65)

1. Ances BM, Ellis RJ: Dementia and neurocognitlve disorders due to HIV-1 infection. Semin. Neurol. 27, 86-92 (2007).
2. Antinori A, Arendt G, Becker JT et al.; Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69, 1789-1799 (2007).
3. Neuenburg JK, Brodt HR, Herndier BG et al.: HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31, 171-177 (2002).
4. Sacktor N: The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 8(Suppl. 2), 115-121 (2002).
5. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ: Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17, 1539-1545 (2003).
6. McArthur JC, Haughey N, Gartner S et al.: Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 9, 205-221(2003).
7. Sacktor N, McDermott MP, Marder K et al.: HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 8, 136-142 (2002).
8. Letendre SL, McCutchan JA, Childers ME et al.: Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann. Neurol. 56, 416-423 (2004).
9. Letendre S, Marquie-Beck J, Capparelli E et al.: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65-70 (2008).
10. Cunningham AL, Naif H. Saksena N et al.: HIV infection of macrophages and '.' pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype. J. Leukoc. Biol. 62, 117-125 (1997).
11. Resnick L, Berger JR, Shapshak P, Tourtellotte WW: Early penetration of the blood-brain-barrier by HIV. Neurology 38, 9-14 (1988).
12. Davis LE, Hjelle BL, Miller VE et al.: Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology, 1736-1739 (1992).
13. Mankowski JL, Clements JE, Zink MC: Searching for clues: tracking the pathogenesis of human immunodeficiency virus central nervous system disease by use of an accelerated, consistent simian immunodeficiency virus macaque model. J. bfch. Dis. 186 (Suppl. 2), S199-208 (2002).
14. Rumbaugh JA, Nath A: Developments in HIV neuropathogenesis. Curr. Pharm. Des. 12, 1023-1044 (2006).
15. Turchan J, Pocernich CB, Gairola C et al.: Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60, 307-314 (2003).
16. Pardo CA, McArthur JC, Griffin JW: HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J. Peripher. Nerv. Syst. 6, 21-27 (2001).
17. + and cytotoxic T lymphocytes are associated with, and may be specific for, human immunodeficiency virus type 1 encephalitis in patients with acquired immunodeficiency syndrome. J. Neurovirol. 12, 272-283 (2006).
18. Wang J, Gabuzda D: Reconstitution of human immunodeficiency virus-induced neurodegeneration using isolated populations of human neurons, astrocytes, and microglia and neuroprotection mediated by insulin-like growth factors. J. Neurovirol. 12, 472-491 (2006).
19. Zink MC, Uhrlaub J, DeWitt J et al.: Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293, 2003-2011 (2005).
20. Jackson AC, Scott CA, Owen J, Well SC, Rossiter JP: Therapy with minocycline aggravates experimental rabies in mice. J. Virol. 81, 6248-6253 (2007).
21. McNicholl IR, McNicholl JJ: On the horizon: promising investigational antiretroviral agents. Curr. Pharm. Des. 12, 1091-1103(2006).
22. Sui Z, Sniderhan LF, Fan S et al.: Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3ß to antagonize nuclear factor-ΚB survival pathway in neurons. Eur. J. Neurosci. 23, 2623-2634 (2006).
23. Dou H, Birusingh K, Faraci J et al.: Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J. Neurosci. 23, 9162-9170 (2003).
24. Robinson B, Turchan J, Anderson C, Chauhan A, Nath A: Modulation of human immunodeficiency virus infection by anticonvulsant drugs. J. Neurovirol. 12, 1-4 (2006):
25. Cysique LA, Maruff P, Brew BJ: Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurol. 6, 42 (2006).
26. Letendre SL, Woods SP, Ellis RJ et al.: Lithium improves HIV-associated neurocognitive Impairment. AIDS 20, 1885-1888 (2006).
27. Sui Z, Fan S, Sniderhan L et al.: Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J. Immunol. 177, 702-711 (2006).
28. Zhang D, Anantharam V, Kanthasamy A, Kanthasamy AG: Neuroprotective effect of protein kinase C-δ inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. 322, 913-922 (2007).
29. Bennasser Y, Bahraoui E: HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-ßII and -δ. Faseb. J. 16, 546-554 (2002).
30. Di Giovanni S, Movsesyan V, Ahmed, F et al.: Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc. Natl Acad. Sci. USA 102, 8333-8338 (2005).
31. Wang F, Corbett D, Osuga H et al.: Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J. Cereb. Blood Flow Metab. 22, 171-182 (2002).
32. Pumfery A, de la Fuente C, Berro R, Nekhai S, Kashanchi F, Chao SH: Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr. Pharm. Des. 12, 1949-1961 (2006).
33. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW: Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126, 1628-1637 (2003).
34. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125, 1297-1308(2002).
35. Leung BP, Sattar N, Crilly A et al.: A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170, 1524-1530 (2003).
36. Waehre T, Damas JK, Gullestad L et al.: Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J. Am. Coll. Cardiol. 41, 1460-1467 (2003).
37. Lea PM 4th, Movsesyan VA, Faden AI: Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br. J. Pharmacol. 145, 527-534 (2005).
38. Movsesyan VA, O'Leary DM, Fan L et al.: mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 296, 41-47 (2001).
39. Domin H, Kajta M, Smialowska M: Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol. Rep. 58, 846-858 (2006).
40. Meisner F, Scheller C, Kneitz S et al.: Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology (2007) (Epub ahead of print).
41. Rothstein JD, Patel S, Regan MR et al.: ß-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77 (2005).
42. Rumbaugh JA, Li G, Rothstein J, Nath A: Ceftriaxone protects against the neurotoxicity of human immunodeficiency virus proteins. J. Neurovirol. 13, 168-172 (2007).
43. Mesters JR, Barinka C, Li W et al.: Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 25, 1375-1384 (2006).
44. Poulter MO, Payne KB, Steiner JP: Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 128, 1-6 (2004).
45. Caporello E, Nath A, Slevin J et al.: The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. J. Neurochem. 98, 146-155 (2006).
46. +-induced cytotoxicity in neuronal PC12 cells. J. Neurosci. Res. 70, 90-96 (2002).
47. Abdul HM, Calabrese V, Calvani M, Butterfield DA: Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-ß peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 84, 398-408 (2006).
48. Eftekharpour E, Holmgren A, Juurlink BH: Thioredoxin reductase and glutathione synthesis is upregulated by t-butylhydroquinone in cortical astrocytes but not in cortical neurons. Glia 31, 241-248 (2000).
49. Abdel-Wahab MH: Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2′-methylphenyl)- 1,2,3,6-tetrahydropyridine (2-methyl-MPTP) in mice. J. Biochem. Mol. Toxicol. 19, 32-41 (2005).
50. Herisley K, Carney JM, Stewart CA, Tabatabaie T, Pye Q, Floyd RA: Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int Rev. Neurobiol. 40, 299-317 (1997).
51. Fong JJ, Rhoney DH: NXY-059: review of neuroprotective potential for acute stroke. Ann. Pharmacother. 40, 461-471 (2006).
52. Ginsberg MD, Becker DA, Busto R et al.: Stilbazulenyl nitrone, a novel antioxidant, is highly neuroprotective in focal ischemia. Ann. Neurol. 54, 330-342 (2003).
53. Pieper AA, Verma A, Zhang J, Snyder SH: Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol. Sci. 20, 171-181 (1999).
54. Szabo C, Pacher P, Swanson RA: Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol. Sci. 27, 626-630 (2006).
55. Azzari C, Rossi ME, Resti M et al.: Changed levels of substance P and somatostatin in HIV-positive children. Pediatr. Med. Chir. 14, 577-581 (1992).
56. Annunziata P: Blood-brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism. J. Neurol. 250, 901-906 (2003).
57. Yousry TA, Major EO, Ryschkewitsch C et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924-933 (2006).
58. Dave RS, Pomerantz RJ: Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J. Virol. 78, 13687-13696 (2004).
59. Vartanian TK, Zamvil SS, Fox E, Sorensen PS: Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology, S42-S49 (2004).
60. Klyubin I, Walsh DM, Lemere CA et al.: Amyloid-ß protein immunotherapy neutralizes Aß oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556-561 (2005).
61. Humbert M, Dietrich U: The role of neutralizing antibodies in HIV infection. AIDS Rev. 8, 51-59 (2006).
62. Devadas K, Boykins RA, Hewlett IK et al.: Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection. Peptides 28, 496-504 (2007).
63. Kowal C, Degiorgio LA, Lee JY et al.: Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl Acad. Sci. USA 103(52), 19854-19859 (2006).
64. Keswani SC, Leitz GJ, Hoke A: Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci. Lett. 371, 102-105 (2004).
65. Digicaylioglu M, Kaul M, Fletcher L, Dowen R, Lipton SA: Erythropoietin protects cerebrocortical neurons from HIV-1/gp120-induced damage. Neuroreport 15, 761-763 (2004).